Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire, UK; Impact Accelerator Unit, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; Haywood Foundation, Midlands Partnership NHS Foundation Trust, Haywood Hospital, Staffordshire, UK.
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.
Osteoarthritis Cartilage. 2022 Feb;30(2):196-206. doi: 10.1016/j.joca.2021.10.003. Epub 2021 Oct 22.
This "Year in review" presents a selection of research themes and individual studies from the clinical osteoarthritis (OA) field (epidemiology and therapy) and includes noteworthy descriptive, analytical-observational, and intervention studies. The electronic database search for the review was conducted in Medline, Embase and medRxiv (15th April 2020 to 1st April 2021). Following study screening, the following OA-related themes emerged: COVID-19; disease burden; occupational risk; prediction models; cartilage loss and pain; stem cell treatments; novel pharmacotherapy trials; therapy for less well researched OA phenotypes; benefits and challenges of Individual Participant Data (IPD) meta-analyses; patient choice-balancing benefits and harms; OA and comorbidity; and inequalities in OA. Headline study findings included: a longitudinal cohort study demonstrating no evidence for a harmful effect of non-steroidal anti-inflammatory drugs (NSAIDs) in terms of COVID-19 related deaths; a Global Burden of Disease study reporting a 102% increase in crude incidence rate of OA in 2017 compared to 1990; a longitudinal study reporting cartilage thickness loss was associated with only a very small degree of worsening in pain over 2 years; an exploratory analysis of a non-OA randomised controlled trial (RCT) finding reduced risk of total joint replacement with an Interleukin -1β inhibitor (canakinumab); a significant relationship between cumulative disadvantage and clinical outcomes of pain and depression mediated by perceived discrimination in a secondary analysis from a RCT; worsening socioeconomic circumstances were associated with future arthritis diagnosis in an innovative natural experiment (with implications for unique research possibilities arising from the COVID-19 pandemic context).
这篇“年度回顾”呈现了临床骨关节炎（OA）领域（流行病学和治疗学）的一些研究主题和个别研究，包括值得注意的描述性、分析性观察性和干预性研究。本综述的电子数据库检索在 Medline、Embase 和 medRxiv 中进行（2020 年 4 月 15 日至 2021 年 4 月 1 日）。经过研究筛选，出现了以下与 OA 相关的主题：COVID-19；疾病负担；职业风险；预测模型；软骨损失和疼痛；干细胞治疗；新型药物治疗试验；针对研究较少的 OA 表型的治疗；个体参与者数据（IPD）荟萃分析的益处和挑战；患者选择——权衡利弊；OA 和合并症；以及 OA 中的不平等。头条研究结果包括：一项纵向队列研究表明，非甾体抗炎药（NSAIDs）在 COVID-19 相关死亡方面没有有害影响；一项全球疾病负担研究报告称，2017 年 OA 的粗发病率比 1990 年增加了 102%；一项纵向研究报告称，软骨厚度损失与疼痛在 2 年内仅略有恶化相关；一项对非 OA 随机对照试验（RCT）的探索性分析发现，白细胞介素-1β抑制剂（卡那单抗）降低了全关节置换的风险；在一项 RCT 的二次分析中，累积劣势与疼痛和抑郁的临床结果之间存在显著关系，这种关系由感知到的歧视介导；在一项创新的自然实验中，社会经济状况恶化与未来关节炎诊断相关（这对 COVID-19 大流行背景下产生独特的研究可能性有影响）。
